reports
- Hela Zarrouk
DKSH DKSH HOLDING AG
MF WENDEL SE
F3C SFC ENERGY AG
MERY MERCIALYS SA
GOE GROUPE GORGE SA
ICAD ICADE SA
TPS ORANGE POLSKA S.A.
WIE WIENERBERGER AG
MMT METROPOLE TELEVISION SA
SAX STROEER SE & CO. KGAA
SHOT SCANDIC HOTELS GROUP
TWEKA TKH GROUP N.V. CERT
BRAV BRAVIDA HOLDING AB
TKO TIKEHAU CAPITAL SCA
DUE DURR AG
IGD IMMOBILIARE GRANDE DISTRIBUZIONE SIIQ S.P.A.
AGR AGRANA BETEILIGUNGS-AG
EAT AMREST HOLDINGS SE
GRE GRENERGY RENOVABLES
VRLA VERALLIA SAS
SFQ SAF-HOLLAND SE
ORP ORPEA
PLNW PLANISWARE
HAVAS HAVAS N.V
- Hela Zarrouk
DKSH DKSH HOLDING AG
MF WENDEL SE
F3C SFC ENERGY AG
MERY MERCIALYS SA
GOE GROUPE GORGE SA
ICAD ICADE SA
TPS ORANGE POLSKA S.A.
WIE WIENERBERGER AG
MMT METROPOLE TELEVISION SA
SAX STROEER SE & CO. KGAA
SHOT SCANDIC HOTELS GROUP
TWEKA TKH GROUP N.V. CERT
BRAV BRAVIDA HOLDING AB
TKO TIKEHAU CAPITAL SCA
DUE DURR AG
IGD IMMOBILIARE GRANDE DISTRIBUZIONE SIIQ S.P.A.
AGR AGRANA BETEILIGUNGS-AG
EAT AMREST HOLDINGS SE
GRE GRENERGY RENOVABLES
VRLA VERALLIA SAS
SFQ SAF-HOLLAND SE
ORP ORPEA
PLNW PLANISWARE
SUNN SUNRISE
HAVAS HAVAS N.V
- Martijn Den Drijver
- Mathijs Geerts Danau
Inventiva FIRST LOOK: preliminary FY25 results hold no surprises
Inventiva reported preliminary FY25 results which hold no surprises, and confirmed its cash-runway guidance, which following the € 149m capital raise announced in November 2025, extends the company's runway to middle of 1Q27. This provides funding beyond the expected topline results from the phase 3 (NATiV3) trial of lanifibranor in MASH which are expected in 2H26. We reiterate our Buy rating and € 7 TP.
- Guy Sips
- Mathijs Geerts Danau
- Wim Hoste
Inventiva reports preliminary 2025¹ fiscal year financial results
Inventiva reports preliminary 2025¹ fiscal year financial results Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits2 as of December 31, 2025Revenues of €4.5 million in 2025Completed a U.S. registered public offering for gross proceeds of approximately $172.5 million (€149 million3)Cash runway expected until the middle of the first quarter of 20274 Daix (France), New York City (New York, United States), February 17, 2026 – (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the developmen...
Inventiva publie ses résultats financiers préliminaires pour l’exercic...
Inventiva publie ses résultats financiers préliminaires pour l’exercice 2025¹ Trésorerie et équivalents de trésorerie à 99,3 millions d’euros, et 131,6 millions d’euros en dépôts à court terme2 au 31 décembre 2025Chiffre d’affaires de 4,5 millions d’euros en 2025Réalisation d’une offre au public aux États-Unis pour un produit brut total d’environ 172,5 millions de dollars (149 millions d’euros)3Horizon de trésorerie prévue jusqu’au milieu du premier trimestre 20274 Daix (France), New York City (New York, Etats-Unis), le 17 février 2026 – (Euronext Paris and Nasdaq :IVA) (« Inventiva » ou ...
- Marc Zwartsenburg
- CEFA
ING Benelux Favourites/Weekly performance and valuation update
We update the performance of our ING Benelux Favourites list as well as all valuation and ranking tables for our coverage universe. Performance on the front page is dated from the 28 January 2026, while historical performance is included on the second page. The methodology for our favourites selection is based on a bottom-up approach with a focus on absolute performance with clear near-term triggers. It is a rolling list, ie, stocks can enter/exit whenever we think opportune. The ING Benelux Fav...
- Jerôme Bodin
CEC CECONOMY AG
BVI BUREAU VERITAS SA
MF WENDEL SE
SZG SALZGITTER AG
DEC JCDECAUX SA
TYRES NOKIAN RENKAAT OYJ
ASY ASSYSTEM SA
GXI GERRESHEIMER AG
PIG HAULOTTE GROUP SA
VOE VOESTALPINE AG
CIE CIE AUTOMOTIVE S.A.
BRNL BRUNEL INTERNATIONAL N.V.
ROVI LABORATORIOS FARMACEUTICOS ROVI S.A.
COFA COFACE SA
ECONT ECONOCOM GROUP SE CLASS D
ALFEN ALFEN NV
TUI TUI AG
NCH2 THYSSENKRUPP NUCERA AG & CO.
SCHOTT PHARMA AG
AQ AQUILA PART PROD COM
AMS AMS-OSRAM AG
- Jerôme Bodin
CEC CECONOMY AG
BVI BUREAU VERITAS SA
MF WENDEL SE
SZG SALZGITTER AG
DEC JCDECAUX SA
TYRES NOKIAN RENKAAT OYJ
ASY ASSYSTEM SA
GXI GERRESHEIMER AG
PIG HAULOTTE GROUP SA
VOE VOESTALPINE AG
CIE CIE AUTOMOTIVE S.A.
BRNL BRUNEL INTERNATIONAL N.V.
ROVI LABORATORIOS FARMACEUTICOS ROVI S.A.
COFA COFACE SA
ECONT ECONOCOM GROUP SE CLASS D
ALFEN ALFEN NV
TUI TUI AG
NCH2 THYSSENKRUPP NUCERA AG & CO.
SCHOTT PHARMA AG
AQ AQUILA PART PROD COM
AMS AMS-OSRAM AG
- Konrad Zomer
Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summi...
Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 Daix (France), New York (United States), February 4, 2025 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that CEO Andrew Obenshain has been invited to participate in a fireside chat at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026. The conference is being held February 11-12, 2026 at the Lotte New Yor...
Inventiva présentera au Guggenheim Emerging Outlook : Biotech Summit 2...
Inventiva présentera au Guggenheim Emerging Outlook : Biotech Summit 2026 Daix (France), New York (États-Unis), le 4 février 2026 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd’hui que son Directeur général, Andrew Obenshain, a été invité à participer à un « fireside chat » lors du prochain Guggenheim Emerging Outlook: Biotech Summit 2026. La conférence se tiendra le...
- ING Helpdesk
Benelux Morning Notes
Aalberts: Preview: Another quarter in no man's land? / Ahold Delhaize: Confirms the acquisition of Delfood / AGEAS: China – state to inject capital into insurers / AkzoNobel: Tepid 4Q25 results and FY26 outlook / D'Ieteren: Belgian car registrations down 19%, 65% of 2019 level, VW down only 5% / Xior Student Housing: Sound organic trends continue, two-year guidance revealed
- ING Helpdesk
Benelux Morning Notes
Eurocommercial Properties: 19% stock dividend take up, refinancing completion and leasing update; Ontex: 2H25 consensus release; Signify: 4Q25 results; prepare for a reset; Staffing Sector: Manpower; 4Q25 beat on better revenue trends, 1Q26 outlook positive; WDP: 2030 ambitions revealed, Italy and Spain to come
- David Vagman
- CFA
- Dirk Verbiesen
- Francesca Ferragina
- Jason Kalamboussis
- Marc Hesselink
- CFA
- Marc Zwartsenburg
- CEFA
- Maxime Stranart
- Michiel Vereycken
- Quirijn Mulder
- Reg Watson
- CFA
- Thymen Rundberg
- Tijs Hollestelle
ING Benelux Favourites/Aedifica, Ageas, ASM International, Basic-Fit, ...
We refresh our ING Benelux Favourites list. We apply a fundamental bottom up approach in which we select stocks which provide the best upside within our Benelux coverage universe and these stocks need clear catalysts. Additions/deletions: We add the following names to the ING Benelux Favourites list: Ageas: Ageas has done multiple deals; its most recent purchase of the 25% stake BNP Paribas had in its Belgian ops, is an accretive deal and we believe makes the Belgian operations ready for a pot...
- Jason Kalamboussis
Ageas/Shaking shackles, coming together/BUY
Moving away from dependence on Asian earnings (now c.30%), while carefully managing its M&A path, we believe AGEAS is well positioned to see an earnings acceleration in the coming years. China upstreams are coming through, while the share price of its Chinese partner CTIH has doubled in 12 months. BNP PARIBAS has increased its stake in the Group (from c.15% to c.23%) at the same time moving out of the Belgian entity AG, and the Belgian government is looking at options to increase its 6.3% stake....
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvre...
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux Daix (France), New York City (New York, United States), January 26, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the half-year report of its liquidity contract with Kepler Cheuvreux. Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resou...
Bilan semestriel du contrat de liquidité de la société Inventiva concl...
Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux Daix (France), New York City (New York, Etats-Unis), le 26 janvier 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique ("MASH"), annonce aujourd’hui le bilan semestriel de son contrat de liquidité conclu avec Kepler Cheuvreux. Au titre du contrat de liquidité portant sur les actions de la Société confié à Kepler Cheuvreux,...
- Ahmed Ben Salem
- Emira Sagaama
- Oddo Sustainability Team
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.